Deans' stroke musings: Advancing the acute treatment of stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, October 23, 2022

Advancing the acute treatment of stroke

So you know nothing about stroke and don't know what to do to improve stroke to 100% recovery. GET THE HELL OUT OF STROKE and let survivors run it!

Advancing the acute treatment of stroke

by University of Science and Technology of China

Distribution of functional outcomes at 90 days in the intention-to-treat population. Credit: New England Journal of Medicine (2022). DOI: 10.1056/NEJMoa2206317

Stroke is the "number one killer" that endangers life and health in China. Statistics released by the National Health Commission show that the total number of stroke patients in China exceeds 28 million, and at least 1 in every 5 deaths is due to stroke.

The latest "China Stroke Report 2020" indicates that there are about 3.94 million new strokes and 2.19 million deaths due to stroke every year in China. It is estimated that the number of stroke patients in the world has exceeded 100 million. The World Stroke Organization has designated October 29 as "World Stroke Day".

Early re-canalization of occluded vessels following acute ischemia stroke is key to improving prognosis. At present, the most effective treatment methods for acute ischemic stroke are intravenous thrombolysis and intra-arterial thrombectomy.

A new study, led by Prof. Wei Hu, director of the stroke center and department of neurology at the first affiliated hospital of the University of Science and Technology of China has demonstrated that in patients who suffered a basilar arterial occlusion, an endovascular thrombectomy in 12 hours will lead to to a better functional outcome compared with standard medical therapy.

In addition, endovascular thrombectomy can significantly improve patients' self-care ability and reduce mortality. This study is the first clinical trial successfully demonstrating the superiority of endovascular thrombectomy in acute basilar artery occlusion.

The research team has named the clinical trial "ATTENTION" in the hope that prevention, treatment and research of strokes will attract an increasing amount of attention. Among all types of stroke, posterior circulation stroke accounts for about one fifth. Acute ischemic stroke caused by basilar artery occlusion is often associated with a poorer prognosis and a higher mortality than intracranial large vessel occlusion in the anterior circulation.

However, due to the lack of high-quality evidence-based clinical trials, the efficacy and safety of endovascular thrombectomy for acute basilar artery occlusion has been difficult to determine. Before the launch of this study, the treatment team of the neurology department of the First Affiliated Hospital of the University of Science and Technology of China had conducted a four-year clinical observational registry trial. The initiation of ATTENTION trial was based on high-quality evidence from the results of the preceding observational trial.

The research was published in the New England Journal of Medicine.